康希诺(06185.HK)午後升幅曾扩至11% 共同研发鼻喷雾式吸入型新冠疫苗正申请紧急使用
康希诺生物-B(06185.HK)共同研发鼻喷雾式/吸入型新冠疫苗正在申请紧急使用,该股逆市两连升,继今早反覆升破20天及10天线後,下午升幅曾扩至11%高见355元,现造347.2元,续升8.5%,成交240万股,涉资8.14亿元。
据内媒上周报道,中国工程院院士陈薇出席浦江一个论坛时表示,新冠疫苗既可透过皮下注射,还可透过鼻喷雾式吸入,後者所需剂量是前者五分一,而且可以形成黏膜免疫。这款由陈薇团队与康希诺生物共同研发鼻喷雾式/吸入型新冠病毒疫苗正在申请紧急使用。此外,康希诺董事长宁学峰上周於青岛一次会议上也透露,康希诺鼻喷雾式/吸入型新冠疫苗现已进入临床二期试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.